Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103853 | 0.89 | HDAC1 (0.75) | HDAC1HSD17B14KDM4EMAPTHSD17B10 | |
| SCHEMBL5703332 | 0.89 | HDAC1 (0.75) | HDAC1HSD17B14KDM4EMAPTHSD17B10 | |
| SCHEMBL30595472 | 0.85 | HDAC1 (0.75) | HDAC1HSD17B14KDM4EMAPTHSD17B10 | |
| SCHEMBL7720792 | 0.85 | LIG1 (0.66) | KDM4EMAPTHSD17B10ALDH1A1HPGD | |
| SCHEMBL10774072 | 0.85 | HDAC1 (0.75) | HDAC1HSD17B14KDM4EMAPTHSD17B10 | |
| Protocatechuic Acid SCHEMBL21283829 | 0.82 | KDM4E (0.66) | HDAC1KDM4EMAPTHSD17B10ALDH1A1 | |
| SCHEMBL7720770 | 0.81 | FASN (0.62) | HDAC1HSD17B14KDM4EMAPTHSD17B10 | |
| SCHEMBL30063629 | 0.81 | LIG1 (0.71) | HDAC1HSD17B14KDM4EMAPTHSD17B10 | |
| SCHEMBL6842062 | 0.81 | HDAC1 (0.69) | HDAC1HSD17B14KDM4EMAPTHSD17B10 | |
| SCHEMBL1947873 | 0.81 | LIG1 (0.71) | HDAC1HSD17B14KDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9798236-B2 | Method for forming pattern having hollow structure | CANON KABUSHIKI KAISHA (JP) | 2017-10-24 | — | — | US | claimed |
| US-4015017-A | Certain biphenyl derivatives used to treat disorders caused by increased capillary permeability | LABORATOIRES PHARMASCIENCE (FR) | 1977-03-29 | — | — | US | claimed |
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11180438-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210171429-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200087236-A9 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2020-03-19 | — | — | US | disclosed |
| CN-107976830-A | Plastic base and the display device for including it | 三星电子株式会社 | 2018-05-01 | — | — | CN | disclosed |
| US-9798236-B2 | Method for forming pattern having hollow structure | CANON KABUSHIKI KAISHA (JP) | 2017-10-24 | — | — | US | disclosed |
| CN-106999382-A | Hair deformation process agent | 花王株式会社 | 2017-08-01 | — | — | CN | disclosed |
| WO-2017106861-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-22 | — | — | WO | disclosed |
| US-6245478-B1 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-12 | — | — | US | disclosed |
| US-5849457-A | Positive-working quinonediazide sulfonic acid ester resist composition utilizing solvent system including 2-heptanone, ethyl lactate, and γ- | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0510671-B1 | Positive resist composition | SUMITOMO CHEMICAL CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| EP-0742489-A1 | Positive-working resist composition | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0510670-B1 | Positive resist composition | SUMITOMO CHEMICAL CO (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-5336583-A | Positive quinonediazide resist composition utilizing mixed solvent of ethyl lactate and 2-heptanone | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0510670-A1 | Positive resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-10-28 | — | — | EP | disclosed |
| EP-0510671-A1 | Positive resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-10-28 | — | — | EP | disclosed |
| US-4015017-A | Certain biphenyl derivatives used to treat disorders caused by increased capillary permeability | LABORATOIRES PHARMASCIENCE (FR) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885HSD17B14 354/4885KDM4E 418/4885 |
| US-11180438-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885HSD17B14 354/4885KDM4E 418/4885 |
| US-20200087236-A9 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885HSD17B14 354/4885KDM4E 418/4885 |
| US-20210171429-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885HSD17B14 354/4885KDM4E 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.